---
$id: https://graph.org.ai/products/commodity/51131818
$type: Product
source: UNSPSC
code: "51131818"
title: "Batroxobin"
class: "51131800"
classTitle: "Coagulants and systemic hemostatic agents"
family: "51130000"
familyTitle: "Hematolic drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Batroxobin

**UNSPSC Code**: 51131818
**Class**: [Coagulants and systemic hemostatic agents](Coagulants and systemic hemostatic agents.mdx)
**Family**: [Hematolic drugs](../Hematolic drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a protease inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 47RYF40GA9. European Medicines Agency schedules Batroxobin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00675MIG. The term BATROXOBIN is an International Non-Proprietary Name (see WHO INN reference publication, Volume 27, No. 10 1973, List 13.). World Health Organization schedules camostat in its Anatomical Therapeutic Chemical (ATC) Classification. BATROXOBIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Batroxobin under HS 35079090 and SITC 51691. SMILES:. As of Q4 2014, BATROXOBIN remains the US FDA Preferred Term for this commodity. . Batroxobin bears US NLM identifiers UMLS ID C0035158 and NCI Concept Code C79483.

